13/01/2026 Ipsen's IPN60340 received the FDA Breakthrough Therapy Designation for AML Ipsen's IPN60340 received the FDA Breakthrough Therapy Designation for AML ( Ref ) The US FDA granted the Breakthrough Therapy Designation to Ipsen's IPN60340 (anti-BTN3A) in combination with venetoclax and azacitidine in first line unfit acute myeloid leukemia. Christelle Huguet, PhD, EVP and Head of R&D, Ipsen: “ This Breakthrough Therapy Designation recognizes both the urgent need for new

18/07/2025 ImCheck’s ICT01 received the Orphan Drug Designation for Acute Myeloid Leukemia ( Ref ) The US FDA granted the Orphan Drug...

Acute myeloid leukemia (AML) is the most common type of leukemia among the adult population and accounts for about 80% of all cases. Despite development of novel treatment options and targeted therapeutics, the 5-year survival rate in adult population is quite low, indicating towards a huge unmet need in AML treatment space. The current infographic concisely highlights the key treatment options for AML and some of the emerging therapeutic stratagems.